Novartis AG (NYSE:NVS) projects a stronger growth trajectory through 2030, lifting expectations for several key medicines and outlining a pipeline strategy it believes will sustain momentum well into the next decade.

• NVS is having a challenging session. See the full story here.

The company updated its mid-term outlook ahead of its Meet Novartis Management event in London, emphasizing higher confidence in long-term demand drivers and upcoming drug launches.

The drugmaker now anticipates a compound annual sales growth rate of 5% to 6% on a constant-currency basis from 2025 to 2030.

"As a pure-play medicines company, Novartis has delivered a strong track record of sales growth with core margin expansion," says Vas Narasimhan, CEO of Novartis.

"Looking ahead, we expect to sustain that momentum over the next five years, driven by assets we already have in hand as well as upcoming launches with multi-billion-dollar sales potential. Over ...